Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Decreased HER2 expression in endometrial cancer following anti‐HER2 therapy

The Journal of Pathology(2023)10.1002/path.6230Source: DataRank Database

Decreased HER2 expression in endometrial cancer following anti‐HER2 therapy is a research paper published in The Journal of Pathology (2023). On theSindex it has a DataRank of 0. It has been cited 11 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access11 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 1.28)OA: bronzeTopics (39)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

David N. Brown ORCID,Arnaud Da Cruz Paula ORCID,Edaise M. da Silva ORCID,Amir Momeni Boroujeni ORCID,Jorge S. Reis‐Filho ORCID

Live enrichment

PubMed:38013631 OpenAlex:https://openalex.org/W4389097853

National Cancer Institute

Grant: P30CA008748

National Institutes of Health

Grant: NCI P50 CA247749 01

NCI NIH HHS

Grant: P50 CA247749

NCATS NIH HHS

Grant: UL1 TR002384

NCATS NIH HHS

Grant: UL1 TR000457

FWCI

1.28

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

bronzeLicense: http://onlinelibrary.wiley.com/termsAndConditions#vor

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/path.6230

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/path.6230

publisherhttps://pathsocjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/path.6230

journalhttps://doi.org/10.1002/path.6230

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38013631

Fields of Study

HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchCell Adhesion Molecules ResearchFemaleHumansErb-b2 Receptor Tyrosine KinasesIn Situ Hybridization, FluorescenceNeoplasm Recurrence, LocalTrastuzumabEndometrial NeoplasmsGene Amplification

MeSH Terms

TrastuzumabFemaleGene AmplificationHumansNeoplasm Recurrence, LocalEndometrial NeoplasmsIn Situ Hybridization, FluorescenceErb-b2 Receptor Tyrosine KinasesReceptor, ErbB-2

Keywords

TrastuzumabImmunohistochemistryTargeted therapyMedicineFluorescence in situ hybridizationCancerCancer researchEndometrial cancerInternal medicineBreast cancerOncologyBiologyGeneGeneticsHER2drug resistancehigh-grade endometrial cancerintratumour heterogeneityuterine serous cancer

Sustainable Development Goals

SDG 0: Good health and well-being